| Literature DB >> 34024286 |
Xiao Hu1,2, Hai Xu3, Shameer Raaj Avishkar Hassea1, Zhiyong Qian1, Yao Wang1, Xinwei Zhang1, Xiaofeng Hou1, Jiangang Zou4.
Abstract
BACKGROUND: Several studies have illustrated the use of echocardiography, magnetic resonance imaging, and nuclear imaging to optimize left ventricular (LV) lead placement to enhance the response of cardiac resynchronization therapy (CRT) in heart failure patients. We aimed to conduct a meta-analysis to determine the incremental efficacy of image-guided CRT over standard CRT.Entities:
Keywords: CRT response; Cardiac resynchronization therapy; Heart failure; Image-guided
Mesh:
Year: 2021 PMID: 34024286 PMCID: PMC8142495 DOI: 10.1186/s12872-021-02061-y
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
The methodological quality of RCTs based on the Cochrane handbook
| Study | A | B | C | D | E | F |
|---|---|---|---|---|---|---|
| Saba | + | ? | + | − | + | ? |
| Khan | + | + | + | − | + | + |
| Sommer | + | − | + | + | − | + |
| Zou | + | − | + | − | + | + |
A, randomization sequence generation; B, allocation concealment; C, blinding of participants, personnel and outcome assessment; D, Incomplete outcome data; E, selective reporting; F, other bias; +, yes; −, no; ?, unclear
Fig. 1Flow diagram for study selection
Baseline characteristics of the included studies and patients
| Study | Country | Study design | CRT intervention | Sample size | Age (year) | Gender male (%) | NYHA class | QRS duration (ms) | Definition of response |
|---|---|---|---|---|---|---|---|---|---|
| Bai et al. [ | United States | Prospective study | Image-guided | 50 | 66 ± 11 | 60 | III or IV: 3.10 ± 0.30 | 153 ± 23 | At least 1 class decrease of NYHA, increase > 20% in LVEF, reduction ≥ 15% in LVESV. fulfill at least 2 of the above 3 criteria |
| Standard | 54 | 64 ± 9 | 74 | III or IV: 3.07 ± 0.26 | 155 ± 29 | ||||
| Khan et al. [ | United Kingdom | RCT | Image-guided | 110 | 72 (65–76) | 77 | III/IV:95/15 | 157 (148–170) | A reduction ≥ 15% in LVESV |
| Standard | 110 | 72 (64–80) | 80 | III/IV:93/17 | 159 (146–170) | ||||
| Saba et al. [ | United States | RCT | Image-guided | 110 | 66 ± 11 | 70 | II/III/IV:16/64/20 | 157 ± 27 | A reduction ≥ 15% in LVESV or ≥ 5% increase in LVEF with no primary end point (death or first HF hospitalization) |
| Standard | 77 | 67 ± 13 | 78 | II/III/IV:8/71/21 | 162 ± 27 | ||||
| Sommer et al. [ | Denmark | RCT | Image-guided | 89 | 71 ± 9 | 78 | II/III/IV:44/44/1 | 167 ± 22 | Improvement in NYHA class, ≥ 10% increase in 6MWT distance, with no death or HF hospitalization |
| Standard | 93 | 71 ± 9 | 80 | II/III/IV:40/48/5 | 165 ± 22 | ||||
| Mele et al. [ | Italy | Retrospective study | Image-guided | 64 | 68.4 ± 9.0 | 77 | II/III/IV:47/15/2 | 153.4 ± 23.6 | A reduction > 15% in LVESV |
| Standard | 64 | 68.4 ± 11.1 | 86 | II/III/IV:37/23/4 | 155.3 ± 16.1 | ||||
| Bertini et al. [ | Italy | Prospective study | Image-guided | 50 | 67.3 ± 9.7 | 74 | II/III/IV:29/17/4 | 156 ± 24 | A reduction ≥ 15% in LVESV |
| Standard | 50 | 65.6 ± 8.4 | 76 | II/III/IV:25/24/1 | 154 ± 30 | ||||
| Salden et al. [ | Netherlands | Prospective study | Image-guided | 6 | 67 ± 3 | 50 | II/III:5/1 | 165 ± 26 | A reduction > 15% in LVESV |
| Standard | 9 | 69 ± 9 | 78 | II/III:7/2 | 160 ± 22 | ||||
| Zou et al. [ | China | RCT | Image-guided | 87 | 62.5 ± 11.5 | 68 | II/III/IV:18/52/17 | 163.57 ± 23.63 | A reduction > 15% in LVESV |
| Standard | 90 | 62.7 ± 11.2 | 72 | II/III/IV:18/55/17 | 161.17 ± 24.16 |
CRT, cardiac resynchronization therapy; LVESV, left ventricular end-systolic volume; LV, left ventricular; EF, ejection fraction; RCT, randomized controlled trial; NYHA, New York Heart Association
Outcomes of the included studies
| Study | CRT treatment | Concordance with the site of latest activation (%) | CRT response (%) | LVEF(%), mean ± SD | LVESV(ml), mean ± SD | Death (%) | HF hospitalization (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow up | Change | Baseline | Follow up | Change | ||||||
| Bai et al. [ | Image-guided | NR | 41 (82) | 23 ± 7 | 34 ± 10 | 11 ± 8.89b | 172 ± 65 | 129 ± 65 | − 43 ± 65 | NR | NR |
| Standard | NR | 34 (63) | 26 ± 6 | 32 ± 9 | 6 ± 7.94b | 159 ± 74 | 141 ± 82 | − 18 ± 78 | NR | NR | |
| Khan et al. 2012 | Image-guided | Concordant: 63 | 72 (70) | 23 ± 6 | 31 ± 9 | 8 ± 7 | 157 ± 56 | 111 ± 43 | − 46 ± 33 | NR | NR |
| Adjacent: 26 | |||||||||||
| Remote: 10 | |||||||||||
| Standard | Concordant: 47 | 57 (55) | 23 ± 7 | 28 ± 10 | 5 ± 8 | 154 ± 52 | 128 ± 50 | − 26 ± 23 | NR | NR | |
| Adjacent: 29 | |||||||||||
| Remote: 25 | |||||||||||
| Saba et al. [ | Image-guided | Concordant: 30 | 50 (57) | 26 ± 6 | 38 ± 12.8a | 12 ± 11 | 140 ± 59 | 110 ± 31a | − 30 ± 29 | 15 (13.6) | 16 (14.5) |
| Adjacent: 55 | |||||||||||
| Remote: 15 | |||||||||||
| Standard | Concordant: 12 | 22 (35) | 26 ± 7 | 35 ± 11.45a | 9 ± 10 | 144 ± 63 | 125 ± 52a | − 20 ± 25 | 15 (19.5) | 21 (27.3) | |
| Adjacent: 54 | |||||||||||
| Remote: 33 | |||||||||||
| Sommer et al. [ | Image-guided | Concordant: 49 | 66 (74) | 25 ± 6 | 37 ± 10.35a | 12 ± 9 | 190 ± 70 | 156 ± 67a | − 34 ± 23 | 1 (1.1) | 3 (3.4) |
| Adjacent: 50 | |||||||||||
| Remote: 1 | |||||||||||
| Standard | Concordant: 43 | 54 (58) | 24 ± 6 | 36 ± 9.08a | 12 ± 8 | 198 ± 69 | 165 ± 56a | − 33 ± 23 | 2 (2.2) | 1 (1.1) | |
| Adjacent: 54 | |||||||||||
| Remote: 2 | |||||||||||
| Mele et al. [ | Image-guided | NR | 48 (64) | 29.1 ± 5.9 | 39.0 ± 9.9 | 9.9 ± 8.6b | 138.4 ± 41.8 | 107.5 ± 43.8 | − 30.9 ± 38.9b | NR | NR |
| Standard | NR | 31 (64) | 29.8 ± 5.0 | 35.3 ± 6.7 | 5.5 ± 6.0b | 140.5 ± 43.1 | 124.4 ± 45.4 | − 16.1 ± 44.3b | NR | NR | |
| Bertini et al. [ | Image-guided | Concordant: 58 | 39 (78) | 29 ± 6 | 42 ± 11 | 13 ± 8.72b | 142 ± 47 | 102 ± 45 | − 40 ± 46.03b | NR | NR |
| Adjacent: 36 | |||||||||||
| Remote: 6 | |||||||||||
| Standard | NR | 28 (56) | 29 ± 6 | 37 ± 9 | 8 ± 9.54b | 148 ± 51 | 121 ± 55 | − 27 ± 53.11b | NR | NR | |
| Salden et al. [ | Image-guided | Concordant: 50 | 6 (100) | 27 ± 6 | 42 ± 6a | 15 ± 5 | 175 (142–216) | NR | − 30 ± 10 | NR | NR |
| Adjacent: 50 | |||||||||||
| Remote: 0 | |||||||||||
| Standard | NR | NR | 25 ± 5 | 35 ± 13.69a | 10 ± 12 | 128 (96–169) | NR | − 19 ± 19 | NR | NR | |
| Zou et al. [ | Image-guided | Concordant and adjacent: 85.5 | 66 (76) | 26.69 ± 6.22 | NR | NR | 187.27 ± 77.94 | 139.07 ± 60.6a | − 48.2 ± 61.6 | NR | NR |
| Remote: NR | |||||||||||
| Standard | Concordant and adjacent: 62.4 | 57 (63) | 27.28 ± 6.17 | NR | NR | 189.52 ± 76.83 | 160.62 ± 67.8a | − 28.9 ± 54.6 | NR | NR | |
| Remote: NR | |||||||||||
NR, not reported; ml, milliliters; SD, standard deviation; HF, heart failure; other abbreviations as in Table 2
aData were estimated based on the results of baseline and change from baseline
bData were estimated based on the results of baseline and follow-up
Fig. 2Forest plot of CRT response between groups. A fixed-effects model and Mantel–Haenszel method were used to pool data. Abbreviations: CI, confidence interval; CRT, Cardiac resynchronization therapy
Fig. 3Forest plot of change in LVEF between groups. A random-effects model and inverse variance (IV) method were used to pool data. Abbreviations: SD, standard deviation; other abbreviations as in Fig. 2
Fig. 4Forest plot of change in LVESV between groups. A random-effects model and inverse variance (IV) method were used to pool data. Abbreviations as in Fig. 3
Fig. 5a Forest plot of a HF hospitalization between groups, b mortality rate between groups. A random-effects model and Mantel–Haenszel method were used to pool data. Abbreviations as in Fig. 2
Fig. 6Forest plot of concordance of LV between groups. A random-effects model and Mantel–Haenszel method were used to pool data. Abbreviations as in Fig. 2
Subgroup analysis for the association of CRT response between groups for each variable
| Variable | Subgroups | No. of studies | No. of patients CRT response (Total) | Test of relationship | Heterogeneity (%) | |||
|---|---|---|---|---|---|---|---|---|
| RR (95%CI) | ||||||||
| Country | United states or Europe | 6 | 542 (883) | 1.37 (1.23–1.52) | < 0.01 | 0 | 0.76 | 0.24 |
| Asia | 1 | 123 (177) | 1.20 (0.98–1.46) | < 0.01 | – | – | ||
| Study design | RCT | 4 | 444 (728) | 1.30 (1.15–1.46) | < 0.01 | 0 | 0.57 | 0.39 |
| observational | 3 | 221 (332) | 1.41 (1.21–1.65) | < 0.01 | 0 | 0.66 | ||
| LVEF (%) | ≥ 25 | 4 | 341 (570) | 1.39 (1.21–1.60) | < 0.01 | 12 | 0.33 | 0.37 |
| < 25 | 3 | 324 (490) | 1.33 (1.21–1.45) | < 0.01 | 0 | 0.98 | ||
| LVESV (ml) | ≥ 150 | 4 | 447 (667) | 1.25 (1.13–1.40) | < 0.01 | 0 | 0.95 | 0.08 |
| < 150 | 3 | 218 (393) | 1.52 (1.26–1.84) | < 0.01 | 0 | 0.78 | ||
| Techniques | ECHO | 3 | 389 (584) | 1.32 (1.17–1.48) | < 0.01 | 0 | 0.5 | 0.73 |
| Non-ECHO | 4 | 276 (476) | 1.36 (1.17–1.59) | < 0.01 | 0 | 0.52 | ||
RR, risk ratio; ECHO, Echocardiography; other abbreviations as in Table. 2
Fig. 7Funnel plot of CRT response between groups